TJN-331

• Description:

  TJN-331 is a potent and orally active TGF-β1 Inhibitor. TJN-331 ameliorates anti-glomerular basement membrane (GBM) nephritis in rats by inhibitng TGF-β1 production, thereby reducing extracapillary proliferation in glomeruli. TJN-331 inhibits mesangial expansion in experimental IgA nephropathy in ddY mice. TJN-331 can be used for the research of nephritis and IgA nephropathy[1][2].

• UNSPSC:

  12352005

• Target:

  TGF-β Receptor

• Related Pathways:

  TGF-beta/Smad

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  O=C(/C=C/C1=CN=CC=C1)N(C)CCC2=CC(OC)=C(C=C2)OC

• Molecular Formula:

  C19H22N2O3

• Molecular Weight:

  326.39

• References & Citations:

  [1]Saegusa Y, et al. TJN-331 improves anti-glomerular basement membrane nephritis by inhibiting the production of intraglomerular transforming growth factor-beta1. Biol Pharm Bull. 2010;33 (8) :1349-1354.|[2]Saegusa Y, et al. (E) -N-[ (3,4-dimethoxyphenethyl) ]-N-methyl-3- (3-pyridyl) -2-propenamide (TJN-331) inhibits mesangial expansion in experimental IgA nephropathy in ddY mice. Clin Exp Nephrol. 2010 Dec;14 (6) :528-35.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [219964-53-1]